Drug Discovery Technologies

Published - Feb 2015| Analyst - Shalini Shahani Dewan| Code - BIO020E
Drug Discovery Technologies
Single User License: $2,750 Member Price: FREE

Report Highlights

The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019. 

Report Includes

  • An overview of the global markets for drug discovery technologies.
  • Analyses of global market trends, with data from 2012-2014, and projections of CAGRs through 2019.
  • A look at the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches.
  • Descriptions of various products such as bioanalytical instruments, high-throughput screening devices, informatics, and microarrays.
  • Analyses of the main positive and negative factors in each sector of the market, potential future trends, and emerging technologies accross different segments of the industry.

Report Scope

BCC Research conducted an assessment of the market, which includes the global and regional breakdown of sales data, market forecasting, available drug discovery technologies in the market, application of the technologies in commercial and research practice, regulatory aspects, patent analysis, market leaders and market share and so forth for the drug discovery technologies.

The report offers a summary of the global drug discovery technologies market along with region-wise sales analysis of regions such as North America (the U.S. and Canada), Europe and emerging markets (Asian countries, South America, parts of Africa, Russia etc.). The application of drug discovery technologies is based on the commercial and R&D uses of those technologies/products/platforms.

The sales data for the global and regional markets were substantiated for the present and projected values through statistical analysis. The technology details in the report are based on their present/prospective application and expediency.

Analyst Credentials

Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jun-2012| Analyst - Marianna Tcherpakov| Code - BIO020D

Report Highlights

The global market for drug discovery technologies and products reached $38.4 billion in 2011. It is expected to expand to $41.4 billion in 2012 and to $79.0 billion in 2017, a compound annual growth rate (CAGR) of 13.8% between 2012 and 2017.

Published - Nov-2007| Analyst - Valarie Natale| Code - BIO020C

Report Highlights

  • The global market for drug discovery technologies increased from $20.2 billion in 2006 to an estimated $22 billion in 2007. It should reach $32.5 billion by 2012, a compound annual growth rate (CAGR) of 8.2%.
  • High throughput screening has the largest share of the market, worth an estimated $8.5 billion in 2007, and is expected to reach $12 billion by 2012, a CAGR of 7.1% over the forecast period.
  • While informatics has the smallest share of the market, worth $725 million in 2007, the segment will see the largest CAGR of 15.7%, as its value rises to $1.5 billion by 2012.
Published - Jul-2001| Analyst - Valarie Natale| Code - BIO020B

Report Highlights

REPORT HIGHLIGHTS

  • New methods for drug discovery and delivery are receiving considerable attention in the pharmaceutical industry and in the media. Trial-and-error discovery methods have been replaced by focused combinatorial synthesis, high throughput systems, and other advanced systems. These new methods have produced agents that have entered clinical trials. As a result of the new technologies, costs and development times are falling, and knowledge about each new agent's mode of action has increased.
  • This updated BCC study examines how the new drug discovery technologies have affected costs and drug development times. It also analyzes how new screening technologies, DNA microarrays, and increasingly sophisticated instruments will affect pharmaceutical discovery. An important section of the report analyzes market sizes and market growth for each technology. The report also includes interviews with executives in the instruments industry and the combinatorial chemistry industry.
  • Molecular biology has given scientists detailed knowledge about basic and complex biological processes. One result of this new knowledge has been an explosion in the development of sophisticated pharmaceutical agents. For example, the number of drug candidates that have been screened in the last ten years has increased by three orders of magnitude: in 1990, approximately 500,000 drug compounds were screened; for the year 2000, that number is estimated at 1.5 billion.

RELATED REPORTS
Share This Report